Nicholas Mosca, MD
Family Medicine · Midwest City, OKNPI 1225568777
Payments from drug & device makers
Across 448 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Novo Nordisk$876
- AstraZeneca$740
- Lilly USA, LLC$740
- Amgen$341
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,21899%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 84 | $1,343 |
| GSK | 83 | $1,109 |
| Novo Nordisk | 58 | $876 |
| AstraZeneca | 40 | $740 |
| Lilly USA, LLC | 50 | $740 |
| Amgen(2 entities) | 21 | $341 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $333 |
| Pfizer | 16 | $257 |
| Antares Pharma, Inc. | 11 | $215 |
| Merck | 13 | $210 |
| Boehringer Ingelheim | 11 | $208 |
| Biohaven Pharmaceuticals, Inc. | 7 | $116 |
| Exact Sciences | 7 | $114 |
| Bayer | 6 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $82 |
| Nabriva Therapeutics, PLC | 3 | $73 |
| Boston Scientific | 1 | $73 |
| Mylan Specialty L.p. | 2 | $63 |
| Eisai Inc. | 4 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Relievant Medsystems, Inc. | 1 | $18 |
| Halozyme Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$7,291 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $59,694 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $33,900 |
| JardianceEmpagliflozin | 20 | $19,845 |
| FarxigaDapagliflozin Propanediol | 16 | $18,407 |
| MounjaroTirzepatide | 17 | $17,630 |
| RybelsusSemaglutide | 11 | $16,542 |
| JanuviaSitagliptin Phosphate | 19 | $13,215 |
| Xtampza ErOxycodone Myristate | 13 | $8,228 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,121 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $3,398 |
| Gabapentin | 101 | $1,917 |
| Varenicline Tartrate | 11 | $1,719 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $1,595 |
| Levothyroxine Sodium | 132 | $1,504 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $876 | $76,23665 claims |
| GSKTrelegy Ellipta | $1,109 | $33,90030 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $740 | $26,52829 claims |
| Boehringer IngelheimJardiance | $208 | $19,84520 claims |
| Lilly USA, LLCMounjaro | $740 | $17,63017 claims |
| MerckJanuvia | $210 | $13,21519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Midwest City
- Carl GriffinMidwest City$110K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.